Literature DB >> 25236506

Prevalence and characterization of pruritus in epidermolysis bullosa.

Christina Danial1, Rasidat Adeduntan, Emily S Gorell, Anne W Lucky, Amy S Paller, Anna Bruckner, Elena Pope, Kimberly D Morel, Moise L Levy, Shufeng Li, Elaine S Gilmore, Alfred T Lane.   

Abstract

Qualitative data suggest that pruritus is a burdensome symptom in patients with epidermolysis bullosa (EB), but the prevalence of pruritus in children and adults with EB and factors that contribute to pruritus are unknown. The objective of the current study was to quantitatively identify and to characterize pruritus that EB patients experience using a comprehensive online questionnaire. A questionnaire was developed to evaluate pruritus in all ages and all types of EB. Questions that characterize pruritus were included and factors that aggravate symptoms were investigated. Patients from seven North American EB centers were invited to participate. One hundred forty-six of 216 questionnaires were completed (response rate 68%; 73 male, 73 female; median age 20.0 years). Using a 5-point Likert scale (1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always), itchiness was the most bothersome EB complication (mean 3.3). The average daily frequency of pruritus increased with self-reported EB severity. Pruritus was most frequent at bedtime (mean 3.8) and interfered with sleep. Factors that aggravated pruritus included healing wounds, dry skin, infected wounds, stress, heat, dryness, and humidity. Pruritus is common in individuals with EB and can be bothersome. Future studies will need to investigate the most effective treatments given to individuals with EB for pruritus.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25236506      PMCID: PMC4315706          DOI: 10.1111/pde.12391

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  24 in total

1.  Endogenous circadian control of the human autonomic nervous system.

Authors:  M F Hilton; M U Umali; C A Czeisler; J K Wyatt; S A Shea
Journal:  Comput Cardiol       Date:  2000

2.  Itch, pain, and burning sensation are common symptoms in mild to moderate chronic venous insufficiency with an impact on quality of life.

Authors:  Maria I Duque; Gil Yosipovitch; Yiong Huak Chan; Ronald Smith; Pavel Levy
Journal:  J Am Acad Dermatol       Date:  2005-09       Impact factor: 11.527

3.  A questionnaire for the assessment of pruritus: validation in uremic patients.

Authors:  G Yosipovitch; I Zucker; G Boner; U Gafter; Y Shapira; M David
Journal:  Acta Derm Venereol       Date:  2001-05       Impact factor: 4.437

4.  Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus.

Authors:  Gil Yosipovitch; A T J Goon; J Wee; Y H Chan; I Zucker; C L Goh
Journal:  Int J Dermatol       Date:  2002-04       Impact factor: 2.736

5.  The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis.

Authors:  G Yosipovitch; A Goon; J Wee; Y H Chan; C L Goh
Journal:  Br J Dermatol       Date:  2000-11       Impact factor: 9.302

6.  Time-dependent variations of the skin barrier function in humans: transepidermal water loss, stratum corneum hydration, skin surface pH, and skin temperature.

Authors:  G Yosipovitch; G L Xiong; E Haus; L Sackett-Lundeen; I Ashkenazi; H I Maibach
Journal:  J Invest Dermatol       Date:  1998-01       Impact factor: 8.551

Review 7.  Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus.

Authors:  Martin Steinhoff; John Bienenstock; Martin Schmelz; Marcus Maurer; Ed Wei; Tamás Bíró
Journal:  J Invest Dermatol       Date:  2006-08       Impact factor: 8.551

8.  The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis.

Authors:  Sarah L Chamlin; Christine L Mattson; Ilona J Frieden; Mary L Williams; Anthony J Mancini; David Cella; Mary-Margaret Chren
Journal:  Arch Pediatr Adolesc Med       Date:  2005-08

9.  Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease.

Authors:  Inbar Zucker; Gil Yosipovitch; Michael David; Uzi Gafter; Geoffrey Boner
Journal:  J Am Acad Dermatol       Date:  2003-11       Impact factor: 11.527

10.  Relative extent of skin involvement in inherited epidermolysis bullosa (EB): composite regional anatomic diagrams based on the findings of the National EB Registry, 1986 to 2002.

Authors:  David T Devries; Lorraine B Johnson; Madeline Weiner; Jo-David Fine
Journal:  J Am Acad Dermatol       Date:  2004-04       Impact factor: 11.527

View more
  10 in total

Review 1.  [Hereditary epidermolysis bullosa in school children and adolescents. Clinical picture and interdisciplinary management].

Authors:  H Ott; C Eich; K Schriek; B Ludwikowski
Journal:  Hautarzt       Date:  2016-04       Impact factor: 0.751

2.  Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.

Authors:  Shaundra Eichstadt; Melissa Barriga; Anusha Ponakala; Claudia Teng; Ngon T Nguyen; Zurab Siprashvili; Jaron Nazaroff; Emily S Gorell; Albert S Chiou; Lisa Taylor; Phuong Khuu; Douglas R Keene; Kerri Rieger; Rohit K Khosla; Louise K Furukawa; H Peter Lorenz; M Peter Marinkovich; Jean Y Tang
Journal:  JCI Insight       Date:  2019-10-03

3.  Evaluation of Treatments for Pruritus in Epidermolysis Bullosa.

Authors:  Christina Danial; Rasidat Adeduntan; Emily S Gorell; Anne W Lucky; Amy S Paller; Anna L Bruckner; Elena Pope; Kimberly D Morel; Moise L Levy; Shufeng Li; Elaine S Gilmore; Alfred T Lane
Journal:  Pediatr Dermatol       Date:  2014-12-29       Impact factor: 1.588

Review 4.  Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Ellie Rashidghamat; John A McGrath
Journal:  Intractable Rare Dis Res       Date:  2017-02

5.  Peripheral neuro-immune pathology in recessive dystrophic epidermolysis bullosa.

Authors:  Madison R Mack; Gwen Wendelschafer-Crabb; Brian D McAdams; Maria K Hordinsky; William R Kennedy; Jakub Tolar
Journal:  J Invest Dermatol       Date:  2014-11-14       Impact factor: 8.551

6.  Oleogel-S10 Phase 3 study "EASE" for epidermolysis bullosa: study design and rationale.

Authors:  Johannes S Kern; Agnes Schwieger-Briel; Sandra Löwe; Mark Sumeray; Charles Davis; Anna E Martinez
Journal:  Trials       Date:  2019-06-11       Impact factor: 2.279

Review 7.  A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.

Authors:  Jean Yuh Tang; M Peter Marinkovich; Eleanor Lucas; Emily Gorell; Albert Chiou; Ying Lu; Jodie Gillon; Dipen Patel; Dan Rudin
Journal:  Orphanet J Rare Dis       Date:  2021-04-13       Impact factor: 4.123

8.  Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Kathrin Dieter; Elke Niebergall-Roth; Silvia Fluhr; Cristina Daniele; Jasmina Esterlechner; Samar Sadeghi; Seda Ballikaya; Leoni Erdinger; Franziska Schauer; Stella Gewert; Martin Laimer; Johann W Bauer; Alain Hovnanian; Giovanna Zambruno; May El Hachem; Emmanuelle Bourrat; Maria Papanikolaou; Gabriela Petrof; Sophie Kitzmüller; Christen L Ebens; Markus H Frank; Natasha Y Frank; Christoph Ganss; Anna E Martinez; John A McGrath; Jakub Tolar; Mark A Kluth
Journal:  JCI Insight       Date:  2021-11-22

9.  Patients' and parents' experiences during wound care of epidermolysis bullosa from a dyadic perspective: a survey study.

Authors:  Petra J Mauritz; Marieke Bolling; José C Duipmans; Mariët Hagedoorn
Journal:  Orphanet J Rare Dis       Date:  2022-08-13       Impact factor: 4.303

10.  Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index.

Authors:  Nicholas H B Schräder; Eva W H Korte; José C Duipmans; Roy E Stewart; Maria C Bolling; André P Wolff
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.